Sight Sciences (SGHT) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
23 Apr, 2026Executive summary
Annual Meeting scheduled for June 4, 2026, at 9:00 A.M. Pacific Time, to be held virtually.
Shareholders are invited to vote on key proposals, including director elections and auditor ratification.
Voting matters and shareholder proposals
Election of two Class II Directors: Gerhard Burbach and Staffan Encrantz, with board recommendation to vote FOR.
Ratification of Deloitte & Touche LLP as independent registered public accounting firm for fiscal year ending December 31, 2026, with board recommendation to vote FOR.
Provision for other business to be transacted as may properly come before the meeting or any adjournment.
Board of directors and corporate governance
Board recommends approval of both director nominees and auditor ratification.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Sight Sciences
- Q4 revenue grew 7% with strong margins; 2026 guidance projects up to 14% growth.SGHT
Q4 202514 May 2026 - Interventional glaucoma and dry eye businesses are accelerating growth with strong clinical and payer momentum.SGHT
Bank of America Global Healthcare Conference 202614 May 2026 - Q1 2026 revenue up 13%, net loss narrowed, and $55.4M litigation award granted.SGHT
Q1 20266 May 2026 - Driving growth with innovative interventional eyecare technologies and strong clinical outcomes.SGHT
Investor presentation6 May 2026 - 2026 meeting seeks director elections, auditor ratification, and introduces performance-based equity.SGHT
Proxy filing23 Apr 2026 - Interventional eye care adoption accelerates, fueled by innovation, reimbursement, and strategic growth.SGHT
25th Annual Needham Virtual Healthcare Conference21 Apr 2026 - OMNI and TearCare drive innovation in eyecare, targeting large, underserved markets.SGHT
investor presentation4 Mar 2026 - Interventional eye care advances with robust clinical data, aiming for payer coverage and renewed growth.SGHT
Morgan Stanley 23rd Annual Global Healthcare Conference3 Feb 2026 - Q2 revenue up 11% sequentially, net loss narrowed, and 2024 guidance set at $81–83M.SGHT
Q2 20242 Feb 2026